Chronic Inflammatory Demyelinating Polyneuropathy

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired neuromuscular disease and the trigger is unknown.1,2

The pathophysiology of CIDP is thought to be based on the autoimmune destruction of peripheral nerve myelin,2 leading to characteristic clinical symptoms of progressive limb weakness with impaired sensory function.2,3 Diagnosis of CIDP is challenging, and laboratory features, electrodiagnostic and clinical criteria are key.4

CIDP treatment includes corticosteroids, intravenous immunoglobulin (IVIG), and/or plasma exchange.2

Chronic inflammatory demyelinating polyneuropathy illustration

Epidemiology

The age of CIDP onset is usually 40 to 60 years, although it can occur at any age. CIDP is twice as common in men than women.5 Available evidence suggests that ethnicity does not influence rates of CIDP.6

Navigating CIDP

CIDP clinical presentation is characterized by insidious onset of symptoms including both proximal and distal progressive, symmetric weakness of the limbs, sensory dysfunction, tingling, paresthesia and pain, and areflexia or diminished tendon reflexes.2,3,19,20 Symptoms are typically ongoing for ≥8 weeks, although disease progression can be monophasic or relapsing-remitting.2,19,20 In some cases, CIDP may be preceded by infection.5
 

Types of CIDP

  • Typical CIDP is characterized by motor and sensory symptoms, paresthesia, difficulty walking, progressive, symmetric proximal and distal muscle weakness, sensory loss, decreased and/or absent deep tendon reflexes, and demyelination per EAN/PNS criteria4,7,8

  • Distal CIDP, also known as distal acquired demyelinating symmetric neuropathy, or DADS, is dominated by sensory symptoms, but motor symptoms may develop4,7,8

    • Symptoms are typically distal and symmetrical, often associated with abnormally increased distal motor latencies and accentuated weakness in the lower limbs, with gait instability4,7,8

    • Approximately two thirds of patients have IgM paraproteinemic neuropathy4

  • Multifocal CIDP encompasses Lewis-Sumner Syndrome, or LSS, and multifocal acquired demyelinating sensory and motor neuropathy, or MADSAM4

    • It is characterized by a multifocal distribution of sensory and motor symptoms that usually affect upper limbs first, with later involvement of lower limbs4,8

    • Cranial nerves are likely to be more frequently involved than in other forms of CIDP, and nerve conduction studies frequently show conduction blocks4,7,8

  • Patients with Motor CIDP present exclusively with motor deficits, with relatively symmetric proximal and distal weakness and normal sensation4

    • Nerve conduction may be normal4,7

    • Patients may deteriorate after corticosteroid treatment4

  • Sensory CIDP is dominated by sensory symptoms

    • Gait ataxia and impairment of sensation (vibration, position and cutaneous) are observed, with weakness appearing later in approximately 70% of patients4

    • Patients may have normal nerve conduction7

 

  • Although rare, Focal CIDP is associated with both motor and sensory symptoms; it usually affects the brachial or lumbosacral plexus, although can affect individual peripheral nerves4

Upcoming & Past Conferences in Allergy & Immunology

  • Upcoming

  • Past

Western Society of Allergy, Asthma and Immunology (WSAAI), 2025

February 9 - 13, 2025 | Link to Event

Annual scientific session uniting allergists, immunologists, nurses, and physician assistants aimed at maintaining the highest standard of practice in allergy care.

Annual Meeting American Academy of Allergy Asthma and Immunology (AAAAI), 2025

February 28 - March 3, 2025 | Link to Event

Premier global educational event for allergists and immunologists, with thousands of attendees each year, discussing allergies, asthma, and immune deficiency disorders.

American Academy of Neurology (AAN), 2025

April 5 - 9, 2025 | Link to Event

Annual meeting in neurology promoting high quality patient-centric care in a variety of topics and specialties through various learning formats.

International Congress on Neuromuscular Diseases (ICNMD), 2024

October 25 - 29, 2024

This international congress offers attendees an updated view on neuromuscular disorders and networking opportunities to increase their international experience and collaborations.

American College of Allergy, Asthma & Immunology (ACAAI), 2024

October 24 - 28, 2024

Global meeting featuring thought leaders from around the world focused on advancing patient care in allergy and immunology.

Takhzyro® (lanadelumab-flyo)

  • Longitudinal Survey of Adult Patients with Hereditary Angioedema Receiving Long-Term Prophylaxis with Lanadelumab
  • Social Determinants of Health in Hereditary Angioedema and their Impact on Patient Outcomes

Immunoglobulin National Society (IgNS), 2024

October 17 - 20, 2024

National conference of IgNS bringing together professionals and practitioners from all disciplines and clinical specialties to advance Ig therapy practice, while providing networking and comprehensive education opportunities.

  • Real-World Characteristics and Disease Management for a Virtual Longitudinal Cohort of Patients with Chronic Inflammatory Demyelinating Polyneuropathy

The European Society for Immunodeficiencies (ESID), 2024

October 16 - 19, 2024

Biennial meeting that covers the latest discoveries in basic and clinical science covering our expanding field, bringing together internationally renowned scientists and clinicians to present and discuss major developments in diagnosis, clinical management, genetics, and immunobiology of inborn errors of immunity.

  • Cost-Effectiveness Of Next-Generation Sequencing Testing In Patients Eligible For Primary Immunodeficiency Screening In The United States

American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), 2024

October 15 - 18, 2024

Annual meeting dedicated to the advancement of neuromuscular, musculoskeletal, and electrodiagnostic medicine.

  • Disease Severity and Healthcare Resource Utilization for Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy: Results from an Integrated Database

Academy of Managed Care Pharmacy Nexus (AMCP Nexus), 2024

October 14 - 17, 2024

Annual event with more than 2,500 members and non-members of the AMCP to engage on the latest innovations and most intentional networking in managed care pharmacy.

Glassia® [Alpha1- Proteinase Inhibitor (Human)]

  • Demographics and Healthcare Resource Utilization in Patients in the United States with Alpha-1 Antitrypsin Deficiency who are Treated with Glassia (Alpha-1 Proteinase Inhibitor)

Southern California Allergy Conference (SCAC), 2024

October 13 - 13, 2024

Annual congress for members of the allergy and immunology community, with a focus on HAE and PID in 2024.

Takhzyro® (lanadelumab-flyo)

  • Lanadelumab Effectiveness and Safety by Disease Activity: EMPOWER/ENABLE Pooled Analysis
  • Understanding treatment switching patterns and continuation rates for patients with hereditary angioedema receiving lanadelumab: analysis of real-world data

American College of Chest Physicians (CHEST), 2024

October 6 - 9, 2024

Annual meeting offering the most up-to-date education in pulmonary, sleep, and critical care medicine through simulation sessions and original research presentations with clinical relevance to practitioners.

Neuromuscular Study Group (NMSG), 2024

September 20 - 22, 2024

Annual conference aiming to advance knowledge about the cause(s), pathogenesis, epidemiology, and clinical manifestations of muscle disease and related neuromuscular disorders and to develop and implement strategies to examine promising therapeutic interventions.

  • A Quantitative Study on the Patient Journey and Experience in Patients with CIDP and MMN
  • Plasma Proteomics and Autoantibody Screening: a Tool for Patient Stratification and Monitoring CIDP Treatment Responses

Consortium of Independent Immunology Clinics (CIIC), 2024

September 13 - 14, 2024

Semi-annual conference of key opinion leaders in the Allergy, Asthma, and Immunology space.

Takhzyro® (lanadelumab-flyo)

  • Understanding treatment switching patterns and continuation rates for patients with hereditary angioedema receiving lanadelumab: analysis of real-world data

Bradykinin Symposium

September 5 - 6, 2024

International experts in the field of bradykinin discuss the genetic, molecular, and cellular drivers of angioedema.

  • Comorbid Conditions in Patients With Hereditary Angioedema: Icatibant Outcome Survey

American Association of Nurse Practitioners (AANP), 2024

June 25 - 30, 2024

A national conference offering exclusive continuing education, legislative policy updates, hands-on workshops, lively exhibitors, and networking opportunities for the nurse practitioner community.

Peripheral Nerve Society (PNS), 2024

June 22 - 25, 2024

The largest peripheral nerve meeting globally, offering the latest international research across specialties in peripheral neuropathy.

  • A Quantitative Study on The Patient Journey and Experience in Patients with CIDP and MMN

HyQvia® (Human Immune Globulin 10% with Recombinant Human Hyaluronidase)

  • Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% For Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Final Results from a Long-Term Safety and Tolerability Study

Association of Pulmonary Advanced Practice Providers (APAPP), 2024

June 20 - 22, 2024

The Association of Pulmonary Advanced Practice Providers (APAPP) is the first association to focus solely on advanced practice providers (APPs) working in the realm of pulmonary medicine. Join over 200 nurse practitioners and physician associates for in-depth reviews and discussions highlighting the latest developments and current concepts in pulmonary, critical care, and sleep medicine.

  • Overcoming Racial and Ethnic Biases in The Diagnosis of Patients with Alpha-1 Antitrypsin Deficiency in The United States Using a Machine-Learning Model

European Academy of Allergy & Clinical Immunology (EAACI), 2024

May 31 - June 3, 2024

The flagship meeting of the EAACI and the world’s largest congress specializing in the field of allergy and clinical immunology.

Eastern Allergy Conference (EAC), 2024

May 30 - June 2, 2024

Regional annual conference discussing the most current information from top experts in allergy, asthma, and immunology.

American Thoracic Society (ATS), 2024

May 17 - 22, 2024

International conference showcasing the latest advances in pulmonary disease, critical illness, and sleep disorders for scientists and clinicians at all stages of their careers.

Professional Society for Health Economics and Outcomes Research (ISPOR), 2024

May 5 - 8, 2024

Leading global conference discussing how to establish, incentivize, and share value sustainable for health systems, patients, and technology developers.

Clinical Immunology Society (CIS), 2024

May 1 - 4, 2024

Annual meeting with the goal of providing a stimulating forum with presentations and discussions on the latest advances in clinical immunology, including primary immunodeficiencies and immune dysregulatory diseases.

Academy of Managed Care Pharmacy (AMCP), 2024

April 15 - 18, 2024

Large assembly of pharmacy and healthcare professionals dedicated to the issues of managed care pharmacy, offering immersive education sessions and keynote presentations.

Takhzyro® (lanadelumab-flyo)

  • Comparison of Real-World Healthcare Resource Utilization and Costs Among Patients With Hereditary Angioedema on Lanadelumab or Berotralstat Long-Term Prophylaxis

American Academy of Neurology (AAN), 2024

April 13 - 18, 2024

Annual meeting in neurology promoting high quality patient-centric care in a variety of topics and specialties through various learning formats.

HyQvia® (Human Immune Globulin 10% with Recombinant Human Hyaluronidase)

  • Infusion-related Costs for HyQvia Compared to Hizentra in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • Patient-reported outcomes with hyaluronidase-facilitated subcutaneous immunoglobulin 10% maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy

National Home Infusion Association (NHIA), 2024

March 23 - 27, 2024

Annual conference ideal for infusion professionals or those seeking opportunities in the industry to come together and explore the latest trends in offering home-based services.

Hereditary Angioedema International (HAEi), 2024

March 15 - 17, 2024

Every second year HAEi gathers HAE patients, caregivers, healthcare professionals, and industry representatives with a sole focus of sharing experience and knowledge on HAE topics.

Annual Meeting American Academy of Allergy Asthma and Immunology (AAAAI), 2024

February 23 - 26, 2024

Premier global educational event for allergists and immunologists, with thousands of attendees each year, discussing allergies, asthma, and immune deficiency disorders.

  • Patient-Reported Outcomes Among Patients With Hereditary Angioedema Within Underrepresented Racial or Ethnic Groups

Takhzyro® (lanadelumab-flyo)

  • Real-World Treatment Outcomes in Patients With Hereditary Angioedema Receiving Lanadelumab or Other Long-Term Prophylaxis
  • Understanding the Impact of Long-Term Prophylaxis Switches for Patients With Hereditary Angioedema
  • Real-World Treatment Outcomes of Lanadelumab in the Prevention of Hereditary Angioedema Attacks: An Interim Analysis of a Polish Prospective, Multicenter, Observational Study (CHOPIN)
  • Real-World Treatment Patterns and Characteristics of Patients With Hereditary Angioedema Treated With Lanadelumab: Results From a US Retrospective Chart Review Study
  • Long-Term Effectiveness and Safety of Lanadelumab in Patients With Hereditary Angioedema From the United States and Canada: Final Data From the EMPOWER Study
  • Burden of Illness in Adult Patients With Controlled and Poorly Controlled Hereditary Angioedema: Findings From a Multinational Survey
  • Burden of Illness in Female and Male Adult Patients With Hereditary Angioedema: Findings From a Multinational Survey and the HELP OLE Study
  • Lanadelumab Effectiveness and Safety in Adolescent Patients With Hereditary Angioedema Aged 12 to <18 Years: Pooled Results From the Real-World ENABLE and EMPOWER Studies

Western Society of Allergy, Asthma and Immunology (WSAAI), 2024

February 4 - 8, 2024

Annual scientific session uniting allergists, immunologists, nurses, and physician assistants aimed at maintaining the highest standard of practice in allergy care.

  • Understanding Social Determinants of Health and Outcomes in Patients With Hereditary Angioedema in the United States
  • Quality of Life Among Patients With Hereditary Angioedema Within Underrepresented Racial or Ethnic Groups

Takhzyro® (lanadelumab-flyo)

  • Real-World Quality of Life in Patients With HAE Receiving Lanadelumab or Other Long-Term Prophylaxis

Medication Resources

HyQvia®

[Immune Globulin Infusion 10% (Human) with recombinant Human Hyaluronidase] Solution

Gammagard Liquid®

[Immune Globulin Infusion(Human)]

Videos

 

Watch videos focused on Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

CIDP Patient Video: Chris

In this video, Chris describes his experience of being diagnosed and living with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

CIDP Patient Video: Julie

Julie shares her experience of being diagnosed with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and the challenges of living with this disorder.

Additional Resources

 

Find materials to help foster a deeper understanding of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

Diagnosis of CIDP Fact Sheet

An overview of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) clinical presentation and diagnostic considerations.

Guideline Recommendations on the Diagnosis of CIDP Fact Sheet

An overview of the task force guideline recommendations for diagnosing Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).